ABSTRACT
Agenesis of the aortic and pulmonary valves is a very rare congenital malformation of the semilunar valves. The literature describes no more than thirty cases of such anomaly in combination with congenital heart disease. Most descriptions include aplasia of either the aortic or pulmonic valve. The combination of such defect in both valves has been described in a much smaller number of scientific papers. In this article, we present a clinical case of the treatment of a patient with agenesis of aortic valve and severely hypoplastic pulmonary valve. As a result circulatory arrest occurred immediately after birth, which required the implementation of cardiopulmonary resuscitation. The child was resuscitated and transferred to the intensive care unit for further examination and treatment.
Subject(s)
Antiviral Agents/therapeutic use , Caproates/therapeutic use , Hepatitis C, Chronic/drug therapy , Imidazoles/therapeutic use , Interferon-alpha/therapeutic use , Polyethylene Glycols/therapeutic use , Precision Medicine/methods , Ribavirin/therapeutic use , Adolescent , Adult , Antibodies, Viral/blood , Antiviral Agents/administration & dosage , Caproates/administration & dosage , Drug Therapy, Combination , Female , Hepacivirus/genetics , Hepacivirus/immunology , Hepacivirus/isolation & purification , Hepatitis C, Chronic/immunology , Hepatitis C, Chronic/pathology , Hepatitis C, Chronic/virology , Humans , Imidazoles/administration & dosage , Interferon alpha-2 , Interferon-alpha/administration & dosage , Liver/pathology , Liver/virology , Male , Middle Aged , Polyethylene Glycols/administration & dosage , RNA, Viral/genetics , Recombinant Proteins/administration & dosage , Recombinant Proteins/therapeutic use , Ribavirin/administration & dosage , Treatment Outcome , Virus Replication/drug effects , Young AdultABSTRACT
PURPOSE OF THE STUDY: clarify the use in the treatment of CHC patients with cytopenia alternative treatment regimens, including leukocyte interferon alpha-alfaferon with ribavirin in combination with immuno-oriented roncoleukin with contraindications to the use of recombinant interferon alpha. MATERIALS AND METHODS: CHC patients with genotype 1b and high viral load, fibrosis of the liver with symptoms dissplenizma manifesting secondary leuco-and/or thrombotic syndrome tsitopenicheskim. Diagnosis of CHC was verified on the basis of clinical, epidemiological, serological and molecular biology (RNA HCV) data. Stage of fibrosis was diagnosed on the basis of ultrasound in combination with dopplerography vessels of the abdominal cavity. As antiviral therapy (OEM) used a combination of drugs "Alfaferon (WBC) with ribavirin depending on body weight and Ronkoleykin" within 12 months. Statistical treatment was performed in the environment of SPSS 11.5. RESULTS: When analyzing the results of the dynamic of clinical and laboratory (including immunological) survey during the observation period (12 months) the patients of the first group have got the positive dynamics of clinical manifestations, disappearance or significant reduction of the severity of astenovegetative and dyspeptic syndromes, reduction of the size of the liver, improvement of the liver function indicators (biochemical response), improvement of the parameters of cellular immunity, reduction of the viral load (virologic response). CONCLUSIONS: 1. CHC patients with contraindications for causal treatment of "standard" forms of recombinant interferon-alpha, using as an OEM combination of drugs "Alfaferon (WBC) with ribavirin depending on body weight and immune-based drug" Ronkoleykin "has a positive impact on clinical manifestations, biochemical parameters of the liver (biochemical response), reduces the amount of RNA HCV in the serum (direct virologic response). 2. Registered with the decrease in the imbalance of cellular immunity (CD3, CD4, CD8, CD16) factors characterizes the substitution of immuno-restoration operation of the proposed treatment regimen. 3. This specific combination of drugs "Alfaferon with ribavirin and Ronkoleykin" inside - is well tolerated, side effects have not been reported.
Subject(s)
Antiviral Agents/administration & dosage , Hepacivirus , Hepatitis C, Chronic/drug therapy , Interferon-alpha/administration & dosage , Ribavirin/administration & dosage , Adult , Antigens, CD/blood , Antigens, CD/immunology , Drug Therapy, Combination , Hepatitis C, Chronic/blood , Hepatitis C, Chronic/diagnosis , Hepatitis C, Chronic/immunology , Humans , Immunity, Cellular/drug effects , Liver Cirrhosis/blood , Liver Cirrhosis/diagnosis , Liver Cirrhosis/drug therapy , Liver Cirrhosis/immunology , Male , Middle Aged , RNA, Viral/blood , RNA, Viral/immunology , Viral Load/drug effects , Viral Load/immunologyABSTRACT
The comparative contribution of environmental factors to morbidity among the preschoolchildren of the town of Orsk was studied by applying currently available methods. Great morbidity is favoured by toxicosis during maternal second-half pregnancy, the poor health status of neonatal babies at birth and by the end of the first year of life, going to the nurseries where vegetable and calorie diets are not observed, the location of kindergartens in the areas with high traffic, high ambient air pollution with sulfuric anhydride and acid, and with substandard drinking water quality. Lower morbidity in children is in turn promoted by greater quantities of vegetables and fruits in the meals both at home and in the nurseries and kindergartens, over 2-month breast feeding, no adverse working conditions in their parents, as well as implementation of conditioning procedures in children.
